


Clarifying Baseline Cognitive Eligibility and Cross-Scale Follow-Up in a Randomized Trial of Remimazolam Tosylate for Laparoscopic Surgery [Letter]

Feng Zhou*, Yuxia Jiao*, Yao Yu, Zhihe Zeng 

Department of Anesthesiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China

*These authors contributed equally to this work

Correspondence: Zhihe Zeng, Email zengzh@dmu.edu.cn

Dear editor

Liu et al¹ deserve credit for studying young and middle-aged adults undergoing laparoscopic surgery, a group overlooked in perioperative neurocognitive research. Remimazolam was associated with less postoperative memory decline than propofol on postoperative day 1, 36.4% versus 53.2%, and day 3, 23.6% versus 37.8%, while the month-1 cognitive endpoint was similar, 6.4% versus 8.1%. However, there are two issues warrant discussion.

One concern is the mismatch between the eligibility criteria and the baseline table. The Methods exclude patients with preoperative MoCA <26. Yet Table 1 reports baseline Pre-MoCA scores of 26 (25–26) in Group R and 26 (24–27) in Group P. The interquartile range includes values below the exclusion threshold. The Methods also state that one point should be added for participants with ≤12 years of education. That matters. In 665 community residents from Western China, education had a larger effect on MoCA than age, effect size 0.272 versus 0.037, and MoCA-based cognitive impairment rates varied from 25.1% to 52.8% depending on the reference approach.² Ratcliffe et al³ analyzed 18,410 participants and concluded that repeated MoCA interpretation should use demographic adjustment and reliable change methods, not a fixed threshold alone. The present report therefore needs an explicit statement on whether Table 1 shows raw MoCA values, education-adjusted values, or both. Otherwise, readers are left uncertain whether this is a reporting ambiguity or a protocol-execution issue.

Another concern is the 1-month conclusion, because the outcome scale changed. In-hospital cognition was assessed with MoCA, but month-1 follow-up used TICS-m by telephone. Table 2 then lists “postoperative cognitive decline” at 1 month as 7/110 versus 9/111. Without a preoperative TICS-m baseline, however, this cannot strictly be called decline from baseline. It is better understood as a one-time screening result. The manuscript also provides two different TICS-m interpretive rules: page 4 states that >31 is normal and <28 indicates severe impairment, whereas page 5 states that an education-adjusted TICS-m score ≤31 is the optimal cutoff for cognitive impairment. That leaves the 28–31 interval unresolved and creates internal inconsistency. Truong et al⁴ reported good TICS-m reliability in 432 older adults, with a Person Separation Index of 0.86, but this supports careful within-instrument interpretation, not direct interchangeability with MoCA across time. A 2024 perioperative guidance likewise emphasizes baseline neurocognitive assessment when postoperative neurocognitive outcomes are inferred.⁵

Reporting both raw and adjusted baseline MoCA distributions, the number of patients below 26 before and after education correction, and a prespecified TICS-m classification scheme would materially strengthen this otherwise valuable study.

Data Sharing Statement

No datasets were generated or analysed during the current study.

Author Contributions

Feng Zhou and Yuxia Jiao are co-first authors.

Yuxia Jiao and Yao Yu: Methodology, Formal analysis, Writing - Original Draft;

Feng Zhou and Zhihe Zeng: Conceptualization, Methodology, Supervision, Writing - Review & Editing. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

There is no funding to report.

Disclosure

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this communication.

References

1. Liu J, Li M, Zhao K, et al. The effects of remimazolam tosylate on postoperative memory function in young and middle-aged patients undergoing laparoscopic surgery. *Drug Des Devel Ther.* 2026;20:580654. doi:10.2147/DDDT.S580654
2. Li H, Peng A, Lai W, et al. Impacts of education level on montreal cognitive assessment and saccades in community residents from Western China. *Clin Neurophysiol.* 2024;161:27–39. doi:10.1016/j.clinph.2024.02.017
3. Ratcliffe LN, Hale AC, McDonald T, et al. The montreal cognitive assessment: norms and reliable change indices for standard and MoCA-22 administrations. *Arch Clin Neuropsychol.* 2024;39(6):747–765. doi:10.1093/arclin/aca013
4. Truong QC, Choo C, Numbers K, et al. Enhancing precision of the Telephone Interview for Cognitive Status-Modified (TICS-M) using the Rasch model. *Psychol Assess.* 2023;35(7):559–571. doi:10.1037/pas0001233
5. Dilmen OK, Meco BC, Evered LA, Radtke FM. Postoperative neurocognitive disorders: a clinical guide. *J Clin Anesth.* 2024;92:111320. doi:10.1016/j.jclinane.2023.111320

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Drug Design, Development and Therapy 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Drug Design, Development and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

<https://doi.org/10.2147/DDDT.S615336>